These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20655918)

  • 21. Long-term cognitive effects of glucocorticoid excess in Cushing's syndrome.
    Forget H; Lacroix A; Bourdeau I; Cohen H
    Psychoneuroendocrinology; 2016 Mar; 65():26-33. PubMed ID: 26708069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal function and morphology in aged Beagle dogs before and after hydrocortisone administration.
    Smets PM; Lefebvre HP; Aresu L; Croubels S; Haers H; Piron K; Meyer E; Daminet S
    PLoS One; 2012; 7(2):e31702. PubMed ID: 22393368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cushing's Syndrome Effects on the Thyroid.
    Paragliola RM; Corsello A; Papi G; Pontecorvi A; Corsello SM
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33808529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of chronic in vivo glucocorticoid excess on the functional characteristics of human skin fibroblasts obtained from patients with endogenous Cushing's syndrome.
    Zervolea I; Pratsinis H; Tsagarakis S; Karavitaki N; Stathakos D; Thalassinos N; Kletsas D
    Eur J Endocrinol; 2005 Jun; 152(6):895-902. PubMed ID: 15941930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic Syndrome in Cushing's Syndrome Patients.
    Ferraù F; Korbonits M
    Front Horm Res; 2018; 49():85-103. PubMed ID: 29894989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucose and lipid metabolism abnormalities in Cushing's syndrome.
    Salehidoost R; Korbonits M
    J Neuroendocrinol; 2022 Aug; 34(8):e13143. PubMed ID: 35980242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucocorticoid-dependent hypertension.
    Mantero F; Boscaro M
    J Steroid Biochem Mol Biol; 1992 Oct; 43(5):409-13. PubMed ID: 1390289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study.
    Fardet L; Petersen I; Nazareth I
    BMJ; 2012 Jul; 345():e4928. PubMed ID: 22846415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different Potent Glucocorticoids, Different Routes of Exposure but the Same Result: Iatrogenic Cushing’s Syndrome and Adrenal Insufficiency.
    Güven A
    J Clin Res Pediatr Endocrinol; 2020 Nov; 12(4):383-392. PubMed ID: 32431136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Glucocorticoids on Bone: What we can Learn from Pediatric Endogenous Cushing's Syndrome.
    Tack LJ; Tatsi C; Stratakis CA; Lodish MB
    Horm Metab Res; 2016 Nov; 48(11):764-770. PubMed ID: 27728929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic comorbidities in Cushing's syndrome.
    Ferraù F; Korbonits M
    Eur J Endocrinol; 2015 Oct; 173(4):M133-57. PubMed ID: 26060052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms in endocrinology: The spectrum of haemostatic abnormalities in glucocorticoid excess and defect.
    Isidori AM; Minnetti M; Sbardella E; Graziadio C; Grossman AB
    Eur J Endocrinol; 2015 Sep; 173(3):R101-13. PubMed ID: 25987566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications.
    Isidori AM; Graziadio C; Paragliola RM; Cozzolino A; Ambrogio AG; Colao A; Corsello SM; Pivonello R;
    J Hypertens; 2015 Jan; 33(1):44-60. PubMed ID: 25415766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation among body composition and metabolic regulation in a male mouse model of Cushing's syndrome.
    Uehara M; Yamazaki H; Yoshikawa N; Kuribara-Souta A; Tanaka H
    Endocr J; 2020 Jan; 67(1):21-30. PubMed ID: 31495810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apoptosis Evaluation in Circulating CD34+-Enriched Hematopoietic Stem and Progenitor Cells in Patients with Abnormally Increased Production of Endogenous Glucocorticoids in Course of Cushing's Syndrome.
    Kawa MP; Sobuś A; Pius-Sadowska E; Łuczkowska K; Rogińska D; Wnęk S; Paczkowska E; Walczak M; Syrenicz A; Machaliński B
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cushing's syndrome.
    Gadelha M; Gatto F; Wildemberg LE; Fleseriu M
    Lancet; 2023 Dec; 402(10418):2237-2252. PubMed ID: 37984386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic in vivo exposure to glucocorticoids prolongs cellular lifespan: the case of Cushing's syndrome-patients' fibroblasts.
    Pratsinis H; Tsagarakis S; Zervolea I; Giannakopoulos F; Stathakos D; Thalassinos N; Kletsas D
    Exp Gerontol; 2002; 37(10-11):1237-45. PubMed ID: 12470837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucocorticoid excess and hypertension.
    Baid S; Nieman LK
    Curr Hypertens Rep; 2004 Dec; 6(6):493-9. PubMed ID: 15527696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased insulin binding and antilipolytic response in adipocytes from patients with Cushing's syndrome.
    Calle C; Carranza MC; Simón MA; Torres A; Mayor P
    Biosci Rep; 1987 Sep; 7(9):713-9. PubMed ID: 3322423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiac disease in Cushing's syndrome. Emphasis on the role of cardiovascular magnetic resonance imaging.
    Moustaki M; Markousis-Mavrogenis G; Vryonidou A; Paschou SA; Mavrogeni S
    Endocrine; 2024 Mar; 83(3):548-558. PubMed ID: 38129722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.